Market Overview

Mid-Afternoon Market Update: Dow Falls Over 100 Points; Kate Spade Gains Amid M&A Speculation


Toward the end of trading Wednesday, the Dow traded down 0.53 percent to 19,838.55 while the NASDAQ declined 0.92 percent to 5,437.13. The S&P also fell, dropping 0.83 percent to 2,250.16.

Leading and Lagging Sectors

Basic materials shares gained around 0.04 percent in trading on Wednesday. Meanwhile, top gainers in the sector included Mechel PAO (ADR) (NYSE: MTL), and New Gold Inc. (USA) (NYSE: NGD).

In trading on Wednesday, utilities shares slipped by 0.66 percent. Meanwhile, top losers in the sector included Empresa Distribuidora y Cmrz Nrt SA(ADR) (NYSE: EDN), down 3 percent, and Korea Electric Power Corporation (ADR) (NYSE: KEP), down 3 percent.

Top Headline

Shares of Galena Biopharma Inc (NASDAQ: GALE), a nano-cap biopharmaceutical company that focuses on hematology and oncology therapeutics for the treatment of unmet medical needs, gained around 40 on Wednesday.

Galena is currently evaluating its GALE-401 therapy for the treatment of thrombocythemia. The company confirmed the regulatory pathway to advance its therapy into a pivotal, Phase 3 trial.

Galena said that after meeting with the U.S. Food and Drug Administration, it can now confirm the development program and the proposed clinical trial is appropriate for a New Drug Application filing as part of the 505(b)(2) regulatory pathway.

Equities Trading UP

Galena Biopharma Inc (NASDAQ: GALE) shares shot up 40 percent to $2.75. Galena is currently evaluating its GALE-401 therapy for the treatment of thrombocythemia. The company confirmed the regulatory pathway to advance its therapy into a pivotal, Phase 3 trial.

Shares of Live Ventures Inc (NASDAQ: LIVE) got a boost, shooting up 12 percent to $29.11 following release of strong earnings report and guidance. Live Ventures reported FY16 earnings of $8.92 per share on revenue of $79 million.

Kate Spade & Co (NASDAQ: KATE) shares were also up, gaining 18 percent to $17.18 amid M&A speculation. The Wall Street Journal reported that Kate Spade is exploring a sale of itself due to pressure from Caerus Investors, an activist investment firm.

Equities Trading DOWN

Anthera Pharmaceuticals Inc (NASDAQ: ANTH) shares dropped 65 percent to $0.700 after the company disclosed that the Phase 3 SOLUTION study with Sollpura has missed the primary endpoint.

Shares of Northern Dynasty Minerals Ltd (NYSE: NAK) were down around 15 percent to $2.08.

VisionChina Media Inc (ADR) (NASDAQ: VISN) was down, falling around 14 percent to $4.90. VisionChina reported Q3 GAAP earnings of $0.63 per share on revenue of $12.8 million.


In commodity news, oil traded up 0.50 percent to $54.17 while gold traded up 0.14 percent to $1,140.40.

Silver traded up 0.29 percent Wednesday to $16.04, while copper fell 0.34 percent to $2.51.


European shares closed mostly lower today. The eurozone’s STOXX 600 gained 0.29 percent, the Spanish Ibex Index dropped 0.34 percent, while Italy’s FTSE MIB Index declined 0.78 percent. Meanwhile the German DAX rose 0.02 percent, and the French CAC 40 slipped 0.01 percent while U.K. shares rose 0.54 percent.


The Johnson Redbook Retail Sales Index rose 1.3 percent year-over-year during the first four weeks of December.

The pending home sales index dropped 2.5 percent to 107.3 in November, compared to 110 in the previous month.

Posted-In: Earnings M&A News Eurozone Commodities Global Intraday Update Markets


Related Articles (EDN + ANTH)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Finish Line Can't Keep Pace With Peers

Analyst: NVIDIA Is Overvalued, But Don't Sell Ahead Of CES